Crossmark

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

Crossref DOI link: https://doi.org/10.1038/s41408-022-00691-9

Published Online: 2022-06-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ghorab, Ahmad https://orcid.org/0000-0003-3429-2737
Al-Kali, Aref https://orcid.org/0000-0002-0824-3715
Elliot, Michelle

Gangat, Naseema https://orcid.org/0000-0002-9104-6172
Alkhateeb, Hasan https://orcid.org/0000-0002-3609-8404
Shah, Mithun https://orcid.org/0000-0002-5359-336X
Liu, Yuanhang

Yi, Cecilia Arana

Murthy, Hemant

Kharfan-Dabaja, Mohamed https://orcid.org/0000-0001-7394-5185
Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
Patnaik, Mrinal https://orcid.org/0000-0001-6998-662X
Litzow, Mark

Badar, Talha https://orcid.org/0000-0003-1548-918X
License Information

Text and Data Mining valid from 2022-06-24

Version of Record valid from 2022-06-24
More Information

Article History

Received: 26 March 2022

Revised: 18 May 2022

Accepted: 7 June 2022

First Online: 24 June 2022

Competing interests

: The authors declare no competing interests.